We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-2.50 | -10.64% | 21.00 | 21.00 | 22.00 | 25.00 | 20.25 | 24.25 | 6,183,038 | 16:40:40 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Services, Nec | 1.04M | -21.69M | -0.0832 | -2.58 | 56.02M |
Date | Subject | Author | Discuss |
---|---|---|---|
12/2/2024 16:31 | Very solid performance today. More tomorrow? | spa362 | |
12/2/2024 14:32 | PDT - Agree & as I see it Angle are in a race to develop content & land a couple of contracts that should return the share price back to somewhere near the post FDA approval levels. The upcoming Liquid Biopsy Summit in San Diego at the end of the month may mean that some of the current negotiations receive a nudge, either closer to or indeed over the finishing line. Angle have a half hour slot & are presenting on 29th Feb (Day 0ne @ 2:30pm) & in good company with fwiw, a few "household names" : Glaxo Smithkline Johnson & Johnson Pfizer Bristol Myers Squibb Novartis AG Regeneron Abbvie Genentech | gooosed | |
12/2/2024 14:21 | “At a market cap of around £50m Angle would be an ideal addition to any of the established players and could be generating billions of dollars from this solution alone. Apart from Prostate, Ovarian, HER2 etc etc The question is how long will they remain independent and at what price will they be taken out. All in my humble opinion of course!DYOR” A reasonable valuation of £300m is equivalent to 111p a share- I think most would be happy with that including the management? | gurunostradamus | |
12/2/2024 14:15 | There certainly seems to be renewed interest here and it is easy to see why. The most recent presentations devoted a lot of time to the ctDNA and ctcDNA comparisons for good reason. The ctDNA testing market is worth about $2 billion a year growing to around $8 billion by the end of the decade. The latest RNS highlighted that ctDNA analysis only provides half of the necessary information. The ctcDNA analysis completes it with additional actionable variants. The existing liquid biopsy players need to add this to their offer. And are at risk of being left behind if a competitor gets ahead of them with a solution. The big pharmas with approved drugs that act on these variants want this information to sell more of their $100,000 plus medications and patients want this information as well. Insurers also want this information and will be happy to pay a few thousand to avoid prescibing drugs that are ineffective and cost hundreds of thousands. And save money with patients that are correctly treated early. At a market cap of around £50m Angle would be an ideal addition to any of the established players and could be generating billions of dollars from this solution alone. Apart from Prostate, Ovarian, HER2 etc etc The question is how long will they remain independent and at what price will they be taken out. All in my humble opinion of course!DYOR | pdt | |
12/2/2024 14:13 | Previous high was 37.4p. Will tag 40p! | kilijarslan | |
12/2/2024 13:59 | Easy doubler here now...... | philjeans | |
12/2/2024 13:29 | Random Tweet? Or Relevant Tweet?- https://twitter.com/ | 5oletrader | |
12/2/2024 13:25 | On Bulletin board heroes today. Target 25p. | ibstar | |
12/2/2024 13:25 | Hmmm shudda held into mebbe. Looking at the volume intraday the numbers on the rises vastly outweigh the volume on the pullback segment. Oops. | boris cobaka | |
12/2/2024 13:24 | https://youtu.be/iSv | ibstar | |
12/2/2024 13:19 | 20p... 22p....28p... likely | atmysignal | |
12/2/2024 13:09 | Worst feeling watching this rise and you're not in. | atmysignal | |
12/2/2024 12:52 | I agree - it is more likely than not that this will push a lot higher over the next month with the potential for more good news plus high profile presentations in the US late this month. Suspect there will be more buying this afternoon | spa362 | |
12/2/2024 12:48 | We wanna pullback, when do we wanit? Nah! | boris cobaka | |
12/2/2024 12:37 | Don't let this move up this month with you on the sidelines.It will drive you crazy knowing you could have bought in below 20pMark this post. | atmysignal | |
12/2/2024 12:31 | Lol did ya miss the boat???? | boris cobaka | |
12/2/2024 12:18 | What’s the betting this still finishes red? | warranty | |
12/2/2024 11:55 | Any mugs spiked ? | havinthelasttoast | |
12/2/2024 11:30 | Down ? Surely it's still up 2.5p on the day at this point ? | dexdringle | |
12/2/2024 11:21 | And down again as per usual. New CEO required here. | middleeast | |
12/2/2024 10:22 | In all seriousness though some of those trades might be a bit 'whiffy'. If an rns comes out later today / tomorrow I'd say someone had access to certain info. Two parties involved? Then it doesn't have to have originated from the agl end. Just spitballing.... | boris cobaka | |
12/2/2024 10:16 | Gap at 45 to 50p | atmysignal | |
12/2/2024 10:15 | Nice volume spike. A hit like a tremor prior to the 'big one'....... | boris cobaka |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions